Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 9;15:3369–3385. doi: 10.2147/JIR.S366927

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Cui et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Potential mechanisms by which MCP protects against cerebral ischemia/reperfusion injury. MCP indicates modified citrus pectin. Cerebral ischemic insult may promote the expression of galectin-3 in microglia, and then trigger the activation of NLRP3 inflammasome in microglia through TLR4/NF-κB signaling pathway, which converts caspase-1 into cleaved-caspase-1. Cleaved-caspase-1 further converts pro-IL-1β into IL-1β, which is then secreted into the extracellular space and contributes to secondary inflammatory response. The neuroprotective effects of MCP on anti-inflammation through blocking expression of galectin-3 was mediated by the axis of TLR4/NF-κB/NLRP3/cleaved-caspase-1/IL-1β in microglia.